Table 3.

Baseline characteristics.

	Thrombectomy group	Propensity score–matched group	P value
Age, y
Median	64 (51-73)	64 (50-75)	.76
Mean	62.2 ± 15.2	62.15 ± 17.2	.97
<65	161 (51.8)	155 (50.2)	.34
65-75	92 (29.6)	83 (26.9)	.29
>75	58 (18.6)	71 (22.9)	.91
Male sex	172 (55.3)	168 (54.4)	.81
Race
White	279 (89.7)	267 (86.4)	.15
Black	21 (6.8)	33 (10.7)	.96
Other	11 (3.5)	9 (2.9)	.33
Body mass index
<18.5 kg/m2	1 (0.3)	6 (1.9)	.97
18.5-24.9 kg/m2	36 (11.6)	39 (12.6)	.66
25-29.9 kg/m2	74 (23.8)	101 (32.7)	.002
>30 kg/m2	200 (64.3)	163 (52.8)	.002
eGFR, mL/min/1.73 m2
≥60	260 (83.6)	243 (78.6)	.056
45 to <60	32 (10.3)	39 (12.6)	.82
30 to 44	17 (5.5)	21 (6.8)	.76
15 to 29	2 (0.6)	5 (1.6)	.87
<15	0 (0)	1 (0.3)	.84
Smoking status
Never	171 (55)	163 (52.8)	.29
Previous	108 (34.7)	109 (35.2)	.56
Current	32 (10.3)	37 (12)	.75
Use of thrombolytics	8 (2.6)	11 (3.6)	.76
Cardiac arrest	7 (2.3)	9 (3.3)	.70
Preprocedure vasopressor	23 (7.4)	10 (3.2)	.01
COVID-19 positive	54 (17.4)	26 (8.4)	.0004
Metastatic cancer	25 (8)	45 (14.5)	.005
Right ventricular strain, CTa	252 (81)	93 (31.1)	<.0001
Right ventricular dysfunction, TTEb	172 (55.3)	75 (33.4)	<.0001
Elevated NT-proBNP or troponinc	274 (88.1)	101 (32.7)	<.0001
CT for diagnosis	311 (100)	299 (96.8)	.0007
Ventilation perfusion for diagnosis	0 (0)	10 (3.2)	.0009

Values are n (%) unless otherwise noted. Given the incomplete data for the PSM group for certain testing, percentages reflect the number of patients with data available.

CT, computed tomography; eGFR, estimated glomerular filtration rate; PSM, propensity score–matched; TTE, transthoracic echocardiogram.

^aRepresents 299 PSM patients who had CT results.

^bRepresents 230 patients who had TTE results.

^cRepresents 302 PSM patients who had either NT-proBNP or troponin assessed.